An anonymous director reports

CARDIOME CLOSES PUBLIC OFFERING OF 11,500,000 COMMON SHARES

Cardiome Pharma Corp. has closed its previously announced underwritten public offering of 11.5 million common shares from treasury, including the underwriters' full exercise of their option to purchase 1.5 million additional shares, at a price to the public of $3.00 (U.S.) per common share, for aggregate gross proceeds to the company of $34.5-million (U.S.), before deducting the underwriting commission and estimated offering expenses payable by the company.

Leerink Partners LLC acted as the sole book-running manager in connection with the offering. Canaccord Genuity, H.C. Wainwright & Co. and Cormark Securities acted as co-managers.

Cardiome intends to use the net proceeds from the offering for the in-licensing of dalbavancin, including for the upfront licensing fee pursuant to the exclusive licence agreement with Allergan PLC, and for milestone payments related to pricing reimbursements and launches. Any remaining net proceeds from the offering will be used for general corporate purposes.

The securities described above were offered pursuant to a shelf registration statement (including a prospectus) previously filed with and declared effective by the Securities and Exchange Commission on March 2, 2016, and were qualified for distribution in Canada by way of a final prospectus supplement to the company's short form base shelf prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering, and a final prospectus supplement and accompanying prospectus relating to the offering, were filed with the SEC and are available for free on the SEC website. Copies of the preliminary prospectus supplement and the accompanying prospectus and the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners. The common shares offered and sold pursuant to the offering were only offered and sold by the underwriters in the United States.

The company relied on the exemption set forth in Section 602.1 of the Toronto Stock Exchange company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq.

We seek Safe Harbor.